Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology

Neurology

Volumn 83, Issue 5, 2014, Pages 434-440

  Monsell, Sarah E ^a   Mock, Charles ^a   Hassenstab, Jason ^b   Roe, Catherine M ^b   Cairns, Nigel J ^b   Morris, John C ^b   Kukull, Walter ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84905867828     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000650     Document Type: Article

References (40)

1. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
2. Jack CR, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;18:1732-1740.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
4. NIA and Reagan Institute Working Group. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-S2.
5. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
6. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13.
7. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1-11.
8. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-216.
9. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord 2007; 21:249-258.
10. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
11. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404.
12. Thal DR, Rüb U, Orantes M, Braak H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
13. Monsell SE, Mock C, Roe CM, et al. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology 2013;80:2121-2129.
14. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychological Test Battery. Alzheimer Dis Assoc Disord 2009;23:91-101.
15. Wechsler D. WMS-R: Wechsler Memory Scale-Revised Manual. Cleveland, OH: Psychological Corp., Harcourt Brace Jovanovich; 1987.
16. Kaplan E. Boston Naming Test. Philadelphia, PA: Lea &Febiger; 1983.
17. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
18. Wechsler D. WAIS-R: Manual: Wechsler Adult Intelligence Scale-Revised. Cleveland, OH: Harcourt Brace Jovanovich [for] Psychological Corp; 1981.
19. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, 2nd ed. Tucson, AZ: Neuropsychology Press; 1993.
20. Hayden KM, Jones RN, Zimmer C, et al. Factor structure of the National Alzheimer's Coordinating Centers uniform dataset neuropsychological battery: an evaluation of invariance between and within groups over time. Alzheimer Dis Assoc Disord 2011;25:128-137.
21. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
22. Dodge HH, Wang C-N, Chang C-CH, Ganguli M. Terminal decline and practice effects in older adults without dementia: the MoVIES project. Neurology 2011;77:722-730.
23. Balota DA, Tse C-S, Hutchison KA, Spieler DH, Duchek JM, Morris JC. Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming. Psychol Aging 2010;25:208-218.
24. Tse C-S, Balota DA, Moynan SC, Duchek JM, Jacoby LL. The utility of placing recollection in opposition to familiarity in early discrimination of healthy aging and very mild dementia of the Alzheimer's type. Neuropsychology 2010;24:49-67.
25. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476-1481.
26. Twamley EW, Ropacki SAL, Bondi MW. Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J Int Neuropsychol Soc JINS 2006;12: 707-735.
27. Knopman DS, Caselli RJ. Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegener Dis Manag 2012;2:183-195.
28. Riley KP, Jicha GA, Davis D, et al. Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis JAD 2011;25:707-717.
29. Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001;56:361-367.
30. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57: 1168-1174.
31. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000;55:370-376.
32. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol 2006;60:688-695.
33. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30: 1026-1036.
34. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012;72:599-609.
35. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576-1582.
36. Vellas B, Aisen PS, Sampaio C, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 2011;95:594-600.
37. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957-965.
38. Grill JD, Monsell SE. Choosing Alzheimer's disease prevention clinical trial populations. Neurobiol Aging 2014; 35:466-471.
39. Kessels RPC, van den Berg E, Ruis C, Brands AMA. The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span. Assessment 2008;15:426-434.
40. Tulsky DS, Price LR. The joint WAIS-III and WMS-III factor structure: development and cross-validation of a six-factor model of cognitive functioning. Psychol Assess 2003;15:149-162.